Siste oppdatering :
19/11/2024
Forskerteamet - Sandoz Biopharmaceuticals, Sandoz GmbH   pdf  
Østerrike
farmasøytiske laboratorier
Sandoz Biopharmaceuticals, Sandoz GmbH
Kundl
Email
Referanser   Referanser   (1)  
1
The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion.
Lamanna W.C, Heller K, Schneider D, Guerrasio R, Hampl V, Fritsch C, Schiestl M. (william.lamanna@sandoz.com)
J Oncol Pharm Practice - 2017 - ;25,2: 269-278

Lister   molekyler Studerte   (1)  
kreft narkotika Injeksjon Rituximab

  Mentions Légales